CareDx enters September with a split personality: a Canaccord Genuity initiation at Buy with a $65 target landed this morning, yet the stock is down 3.6% on the week and carrying an 11.2% short interest that has barely budged. The tension between an improving analyst consensus and a still-elevated short base is the defining feature of this setup.
The Street is moving more constructively on CDNA. Today's Canaccord initiation — $65 target, Buy rating — is the highest published target in the coverage group and implies roughly 33% upside from the current $48.97. BTIG's Mark Massaro has been consistently bullish all year, most recently lifting his target to $60 after Q2 results in early August. The consensus sits at Buy, with a mean target of $54.14. Bulls point to strong volume growth in transplant testing, an expanding oncology footprint, and a financial profile that ranks in the 99th percentile on EPS surprise and the 91st percentile on 30-day earnings momentum — one of the cleaner beat-and-raise stories in diagnostics. The lone holdout is HC Wainwright, which kept its Neutral rating and $46 target after Q2, essentially flagging the stock as fully valued at current levels. That $46 handle is now fractionally below where the stock trades, which makes the Wainwright stance a live point of contention. Valuation multiples reflect a meaningful re-rating: the price-to-book has expanded by 2.5x over the past 30 days, and the trailing P/E has climbed roughly six points in the same window to just over 40x. EV/EBITDA, meanwhile, has compressed by 8 turns — a sign that earnings are growing faster than the market cap is expanding.
The short side tells a more stubborn story. At 11.2% of the free float, CDNA's short interest is genuinely elevated, and despite the post-Q2 rally that took the stock up more than 23% in a single day, short sellers have not materially covered. The position has edged down roughly 0.2% on the week and is actually up 3.3% over the past month — meaning new shorts were added into the July rally rather than squeezed out. Days-to-cover at the most recent FINRA settlement was 5 days, a non-trivial covering burden. The borrow market, however, offers no particular pressure: availability is essentially unconstrained at the platform ceiling, with more than 32 million shares available versus roughly 5.7 million shorted. Cost to borrow has risen 27.5% this week to 0.61%, but in absolute terms that remains low — shorts are paying almost nothing to maintain their positions. The ORTEX short score sits at 51.7, modestly in the middle of its range and drifting slightly lower over the past two weeks, consistent with a position that is large but not accelerating.
Options positioning is notably defensive for a stock that has nearly doubled this year. The put/call ratio at 2.92 is well above typical biotech levels, though it has eased from the 4.88 peak hit in early August just before Q2 earnings. That peak was the highest of the past 52 weeks; the current reading is back toward the 20-day average of 3.28. The direction of travel — PCR falling from its extreme — suggests the most acute hedging demand has passed, but the ratio remains far above the 52-week low of 0.07, meaning call buyers have not yet taken control of the options market. Investors are still paying for protection rather than reaching for upside.
The Q2 print on July 30 was the clearest fundamental moment of the year: CareDx posted a 23.4% single-day gain, extending to 26.5% over the following five days. That move was large enough to flush a significant portion of the prior short base — short shares dropped from roughly 7.9 million in late July to just above 5.1 million by August 10 — but the subsequent re-building of positions to current levels (5.7 million shares) suggests bears view the post-earnings price as an opportunity rather than a capitulation point. The next earnings event is pencilled in for November 4, giving the short-versus-analyst tension roughly two months to resolve.
BlackRock recently updated its 13G/A filing, disclosing a 9% stake as of late July and adding 292,000 shares in the period. ARK Investment Management holds just under 3.8% and made no changes last quarter. Baron Capital trimmed aggressively — down more than a million shares — which partially offsets the BlackRock build. All 13D/G positions are event-driven disclosures around the 5% threshold; stakes are as last disclosed, and holders dropping below 5% may not file again.
What to watch: the Canaccord initiation at $65 sets a new high-water mark for the coverage group and may prompt other firms to revisit their targets — the gap between the current price and the bull case is wide enough that a second analyst moving into that range would represent a meaningful consensus shift, while any reimbursement news touching transplant diagnostics could quickly test which side of the short-versus-Street debate carries more weight into November earnings.
See the live data behind this article on ORTEX.
Open CDNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
